PROCTER & GAMBLE HEALTH
|
|
BOM : 500126     NSE : PGHL     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Feb 17,2025 |
Price(EOD): ₹ 5,299.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 8,797.25 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
PROCTER & GAMBLE HEALTH | 0.8% | -3.5% | 1.9% |
SUN PHARMACEUTICAL INDUSTRIES | 0.8% | -3.5% | 12.9% |
CIPLA | 1.4% | 1.9% | 2.5% |
DR REDDYS LABORATORIES | -1% | -7.9% | -4.4% |
ZYDUS LIFESCIENCES | -1.9% | -7.1% | 2.5% |
DIVIS LABORATORIES | -0.5% | -1.3% | 57.3% |
MANKIND PHARMA | -4.3% | -13.3% | 8.5% |
TORRENT PHARMACEUTICALS | -0.9% | -2.8% | 16.8% |
LUPIN | -2% | -5% | 22.6% |
FUNDAMENTAL ANALYSIS OF PROCTER & GAMBLE HEALTH
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF PROCTER & GAMBLE HEALTH
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
37.19
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 236.57 Cr
[Latest Qtr - Dec2024 - Standalone Results ] 16.61
P/B Calculated based on Book Value of Rs 529.71 Cr
[Latest Year - Jun2024 - Standalone Results ] 7.59
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
58% 73% 54% |
SHARE PRICE MOMENTUM OF PROCTER & GAMBLE HEALTH
PROCTER & GAMBLE HEALTH vs SENSEX
DEBT OF PROCTER & GAMBLE HEALTH
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Jun2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF PROCTER & GAMBLE HEALTH
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF PROCTER & GAMBLE HEALTH
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-1.16% 8.23% 9.24% 10.41% |
-0.06% 21.43% 22.03% 26.13% |
QtrlyTrend |
4 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
PROCTER & GAMBLE HEALTH related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 500 | -3.3% | -4.6% | 3.2% |
S&P BSE HEALTHCARE | -4.4% | -5.4% | 15% |
S&P BSE ALLCAP | -5% | -5.4% | 3.9% |
S&P BSE 400 MIDSMALLCAP | -6% | -10.1% | 1.5% |
S&P BSE MIDSMALLCAP | -6.7% | -11.3% | 1.3% |
You may also like the below Video Courses
FAQ about PROCTER & GAMBLE HEALTH
Is PROCTER & GAMBLE HEALTH good for long term investment?
As on Feb 17,2025, the Fundamentals of PROCTER & GAMBLE HEALTH look Strong and hence it may be good for long term investment! See Financial Performance of PROCTER & GAMBLE HEALTH . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is PROCTER & GAMBLE HEALTH UnderValued or OverValued?
As on Feb 17,2025, PROCTER & GAMBLE HEALTH is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of PROCTER & GAMBLE HEALTH ?
As on Feb 17,2025, the Intrinsic Value of PROCTER & GAMBLE HEALTH is Rs. 3,364.66 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 3,364.66
Fair Value [Median EV / Sales Model] : Rs. 3,055.16
Fair Value [Median Price / Sales Model] : Rs. 3,435.27
Estimated Median Fair Value of PROCTER & GAMBLE HEALTH : Rs. 3,364.66
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.